NCT05177939

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

Phase III Study to Evaluate the Efficacy and Safety of NPB-01 in Patients With Autoimmune Encephalitis Refractory to Steroid Pulse Therapy

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Nihon Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.

Conditions

• Autoimmune Encephalitis

Interventions

Type	Name	Description
DRUG	NPB-01	NPB-01 will be administered for the treatment of autoimmune encephalitis
DRUG	NPB-01-ME	NPB-01-ME will be administered for the treatment of autoimmune encephalitis

Timeline

• Start date: 2022-03-03
• Primary completion: 2024-05-31
• Completion: 2024-10-31
• First posted: 2022-01-05
• Last updated: 2022-12-01

Locations

1 site across 1 country: Japan